Critical Updates in Kidney, Prostate, and Bladder Cancer from ASCO 2023 with Dr. Toni Choueiri

August 24, 2024
Conferences ASCO 2023
Share This:

Key Points

TALAPRO-2: Ph3 study of talazoparib + enzalutamide vs placebo + enzalutamide as first-line (1L) treatment for mCRPC with homologous recombination repair (HRR) gene alterations
CLEAR: 4-year follow-up of lenvatinib plus pembrolizumab vs sunitinib in pts with advanced renal cell carcinoma
CONTACT-03: efficacy and safety of atezolizumab plus cabozantinib vs cabozantinib alone after progression with prior checkpoint inhibitor in metastatic renal cell carcinoma
THOR: Erdafitinib vs chemo in pts with advanced or metastatic urothelial cancer with select FGFR alteration
Dr. Toni Choueiri
Profile

Discussing GU (Genitourinary) Cancer ASCO 2023 Highlights

Focusing on practice changing studies with Dr. Toni Choueiri, Director, Lank Center for Genitourinary Oncology and Professor of Medicine at Harvard Medicine School – Dana-Farber Cancer Institute.

Tags:
Dr. Toni Choueiri Bladder Cancer Critical Updates in Kidney

Related Posts